biosimilars in the us oncology market (2nd edition)

BIOSIMILARS IN THE US ONCOLOGY MARKET(2ND EDITION)

J U L Y , 2 0 1 6

P R E V I E W O F

REPORT OVERVIEW

WHAT YOU WILL LEARN

How you can use this report

This report provides data and insights from 101 US-based, board-certified oncologists or hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology.

Use the data contained in this report to better understand how US-based oncologists will make prescribing decisions in a marketplace that includes biosimilar oncology options and how this has changed since 2012.

D A T A C O L L E C T I O N I N Q 1 , 2 0 1 6

O N L I N E P A N E L A N D O N L I N E

S U R V E Y

1 0 1 O N C O L O G I S T S F R O M T H E U S

31 PAGES

21 CHARTS AND

GRAPHS

VALUABLE FOR

MAJOR SECTIONS:1. Statistical Significance

2. Respondent Qualifications

3. Summary Findings

4. Study Data

• Familiarity with biosimilars

• Expected pricing/discount levels

• Preferred primary endpoints

• Influence the manufacturer plays in the prescribing decision

• How the data have changed since 2012

• Use this report to inform your market access strategies, reimbursement plans, and manufacturing capacity planning.

• Better inform your sales and marketing efforts by understanding the benefits and barriers physicians see in prescribing biosimilars.

FOR PHARMA• Market Access

• Regulatory

• Manufacturing

• Marketing

Introduction

SMARTER QUESTIONS SMARTER ANSWERS

Full Table of Contents on next page.

CONTRACT RESEARCH ORGANIZATIONS

GENERIC MANUFACTURERS

PBM & PAYER ORGANIZATIONS

SPONSOR/INNOVATOR COMPANIES

http://isrreports.com

Introduction


21CHARTS

AND GRAPHS

SAMPLE PAGES

TABLE OF CONTENTS

FOR FULL TABLE OF CONTENTS, PLEASE DOWNLOAD THE FULL PREVIEW AT:

HTTP://WWW.ISRREPORTS.COM/REPORTS/BIOSIMILARS-IN-THE-US-ON-COLOGY-MARKET-2ND-EDITION/


Introduction


Introduction

STUDY DATA

17www.ISRreports.com ©2016 Biosimilars in the US Oncology Market (2nd Edition)

Familiarity with BiosimilarsWith no definition of Biosimilars given upfront, current findings show that 88% of oncologists classify themselves as at least “Familiar” with Biosimilars� Compared to 2012, two times the number of respondents are currently “Very familiar” with Biosimilars�

Furthermore, while 15% of respondents had “never heard of” Biosimilars four years ago, only 2% of respondents report the same views in present day�

“How familiar are you with Biosimilars?”

After asking the “familiarity” question to begin the survey, respondents were provided with the following definition:

“For definitional purposes, Biosimilars can be defined as: Biosimilars or Follow-on biologics are terms used to describe officially-approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product�

Biosimilars are also referred to as subsequent entry biologics (SEBs) in Canada� Reference to the innovator prod-uct is an integral component of the approval� In short, Biosimilars are “generic” products for biologic products, whereas traditional “generic” products are traditionally based on chemical products�”

BIOSIMILARS IN THE US ONCOLOGY MARKET (2ND EDITION)


© Industry Standard Research

This is an enterprise license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR ([email protected]).

S A M P L E P A G E :

FAMILIARITY WITH BIOSIMILARS

Report provides comparative data from 2012 to show how opinions and beliefs have changed over time.

C L O S E R L O O K

<< The percentage of US oncologists that are “very familiar” with biosimilars has doubled since 2012.

Data available in the full report, which can be found at:

www.ISRreports.com

Introduction

STUDY DATA

17www.ISRreports.com ©2016 Biosimilars in the US Oncology Market (2nd Edition)

Familiarity with BiosimilarsWith no definition of Biosimilars given upfront, current findings show that 88% of oncologists classify themselves as at least “Familiar” with Biosimilars� Compared to 2012, two times the number of respondents are currently “Very familiar” with Biosimilars�

Furthermore, while 15% of respondents had “never heard of” Biosimilars four years ago, only 2% of respondents report the same views in present day�


After asking the “familiarity” question to begin the survey, respondents were provided with the following definition:

“For definitional purposes, Biosimilars can be defined as: Biosimilars or Follow-on biologics are terms used to describe officially-approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product�

Biosimilars are also referred to as subsequent entry biologics (SEBs) in Canada� Reference to the innovator prod-uct is an integral component of the approval� In short, Biosimilars are “generic” products for biologic products, whereas traditional “generic” products are traditionally based on chemical products�”

BIOSIMILARS IN THE US ONCOLOGY MARKET (2ND EDITION)


© Industry Standard Research

This is an enterprise license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR ([email protected]).


Introduction


FOR ADDITIONAL SAMPLE PAGES, PLEASE DOWNLOAD THE FULL PREVIEW AT:



Introduction


ORDERING INFORMATION

Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email [email protected], or follow us on twitter @ISRreports.

ABOUT INDUSTRY STANDARD RESEARCH

>> R E G I S T E R N O W>>Receive $250 instant credit towards any ISR report

>>Earn 10% credit towards all future purchases

>>Receive advanced notifications on ISR’s latest reports and free resources

SAVE ON THIS, OR ANY ISR REPORT, BY CREATING A FREE ACCOUNT

FOR PRICING AND ORDERING INFORMATION, PLEASE DOWNLOAD THE FULL PREVIEW AT:



Introduction


TO LEARN MORE: CONTACT US AT [email protected] OR +1(919)301-0106

Biosimilars & Biologics

Clinical Trial Recruitment &

Retention

Commercialization Department Models & Structures

Trends & Technologies

Manufacturing Service Provider Quality Benchmarking

CUSTOM RESEARCH

UNDERSTAND YOUR MARKETSLeverage ISR’s experience and institutional knowledge to create a fit-for-purpose market research project that addresses the business decisions you need to make.

Are you:• Developing a new product or service?• Evaluating a new market?• Targeting a new customer segment?• Entering a new geography?• Needing a deeper understanding of your

customer or potential customer base?

UNDERSTAND YOUR CUSTOMERSWho makes the decisions and in what contexts? ISR can help you gain a deeper understanding of your customers’ decision-making units (DMUs) and decision-making processes (DMPs).

Key Questions Addressed:• What motivates the purchase decision?• How are companies, products, solutions, and/or

brands evaluated?• What factors drive the final buying decision?• Where are your customers won or lost in the

purchasing process?• Why were specific opportunities won or lost?• How do you keep customers engaged and

manage their loyalty over time?

CUSTOM RESEARCH SERVICES• Investigator Forum• Brand, Advertising, and Message Testing• Loyalty Management• New Product and Service Development• Competitive Intelligence• Strategy War Games• MORE

S O M E T H I N G T O C O N S I D E R

DISTINCTIVE – Receive novel insights from industry decision-makers on topics including: service provider quality, patient recruitment, biosimilars, clinical technology, manufacturing, clinical operations, and commercial activities.

UNRESTRICTED – ISR doesn’t sell seats. Instantly obtain access for all employees within your organization

AFFORDABLE – Receive access to ALL reports in ISR’s library, as well as those released during your subscription period. ISR’s competitive library pricing equates to the cost of a few individual report purchases.

LIBRARY ACCESS SUBSCRIPTIONISR’s library access subscription provides your entire organization access to our full library of syndicated market research reports (100+ titles) plus access to all reports (~25 per year) released during your subscription period. Our research categories include:

www.ISRreports.com

Introduction


www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 8

act with confidenceTHE ISR DIFFERENCE

Mostly primary research; always appropriate for the topic

One size fits all; usually publically available data

To learn more, visit www.ISRreports.com

ISR’S REPORTS

THECOMMON

SYNDICATEDREPORT

VS.

RESEARCH METHODS

ISR’s proprietary data tools and channelssupport fast, high quality data collection

Struggle to recruit the right targets and enough of them

DATA COLLECTION

Sophisticated screening ensures genuine decision-makers make up respondents

Undisclosed methodologies and respondent demographics

RESPONDENTS

Robust sample sizes that instill confidence

Often insucient industry representationthat leaves you defending results

SAMPLE SIZE

Decades of experience means more insights that are immediately usable

Junior analysts capable of reporting numbers

ANALYSTS

ISR’S HEALTH PANELThe industry’s fastest growing panel of health care and pharmaceutical

professionals, with nearly 1,500 members worldwide.

BYJOB

LEVEL

Director 46%

Manager 29%

C-level 13%

VP 10%

BYEXPERIENCE

IN YEARS

16-20 years 23%

11-15 years 24%

6-10 years 11%

3-5 years 5%

20+ years 37%

BYCOMPANY

TYPE

Other 6%

Sponsor 78%

CRO 6%

ResearchSite 10%


www.ISRreports.com

http://www.isrreports.com

biosimilars in the us oncology market (2nd edition)

Health & Medicine